1. In this randomized controlled trial, cyclophosphamide-tacrolimus-mycophenolate mofetil was associated with lower rates of graft-versus-host disease (GVHD) compared to tacrolimus-methotrexate in patients undergoing hematopoietic stem-cell transplantation (HSCT). 2. There were no significant differences between groups for overall survival. Evidence Rating Level: 1 (Excellent) Study Rundown: GVHD is a major complication of HSCT. The combination of